October 10, 2024
Bio-Path Holdings Secures $4.0 Million in Recent Private Placement: An Analysis of Their Financial Maneuvers and Market Position Bio-Path Holdings, Inc. (NASDAQ: BPTH), a Houston-based biotechnology company focused on developing innovative targeted nucleic acid cancer therapies with its proprietary DNAbilize liposomal delivery and antisense technology, recently announced a significant financial move by closing a private placement worth $4.0 million. This transaction, which involved the issuance and sale of shares priced at-the-market under Nasdaq rules, is indicative of the company s ongoing efforts to bolster its capital and pursue its mission of innovating cancer treatment. This article explores the details of this transaction, the historical context, and its implications for Bio-Path Holdings as it navigates a challenging market landscape. Details of the Recent Private PlacementOn October 10, 2024, Bio-Path disclosed the successful closing of a previously announced private placement. In this transaction, the company sold an aggregate of 4,597,702 shares of its common stock, alongside series A warrants and short-term series B warrants to purchase up to 6,407,657 shares of common stock at a purchase price of $0.87 per share. The associated warrants have an exercise price of $1.00 per share and will only become exercisable following stockholder approval. The series A warrants will last for five years post-approval, while the short-term series B warrants are valid for 24 months.
|
June 5, 2024
Bio-Path Holdings Successfully Closes Private Placement, Bolstering its Cancer Drug Development Portfolio Houston-based biotechnology company, Bio-Path Holdings, Inc. (NASDAQ:BPTH), announced yesterday the completion of its private placement, paving the way for the issuance and sale of nearly 1.81 million shares of its common stock, along with series A and short-term series B warrants. This development marks a significant step forward for Bio-Path as it leverages its proprietary DNAbilize liposomal delivery and antisense technology to advance its targeted nucleic acid cancer drug pipeline. The private placement saw Bio-Path secure $4 million from institutional investors at a purchase price of $2.21 per share of common stock. The issuance also includes accompanying warrants priced at-the-market in accordance with Nasdaq rules. The series A warrants and short-term series B warrants possess an exercise price of $2.00 per share and are immediately exercisable upon issuance. The series A warrants are set to expire after five years from the date of issuance, while the short-term series B warrants will expire twenty-four months from the issuance date.
|